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Abstract
Background: Studies investigating the association between the methylenetetrahydrofolate reductase (MTHFR) gene
1298A>C polymorphism and the risk of breast cancer have reported inconsistent results. So, we performed this
updated meta-analysis and tried to give a more precise estimation of association between MTHFR gene 1298A>C
polymorphism and breast cancer susceptibility.
Methods: Relevant studies published before 1 January 2016 were identified by searching PubMed and EMBASE.
The strength of relationship between the MTHFR gene 1298A>C polymorphism and breast cancer susceptibility was
assessed using odds ratio (OR) and corresponding 95 % confidence interval (95 % CI). The meta-analysis was
performed using Stata 11.0 software.
Results: A total number of 38 case-control studies including 18,686 cases and 22,299 controls were identified. No
association was found in five genetic models (dominant model: OR = 0.99, 95 % CI 0.99–1.00, P = 0.218; recessive
model: OR = 1.00, 95 % CI 0.97–1.02, P = 0.880; homozygote genetic model: OR = 0.99, 95 % CI 0.98–1.01, P = 0.390;
heterozygote genetic model: OR = 0.99, 95 % CI 0.97–1.00, P = 0.138; and allele contrast genetic model: OR = 0.99,
95 % CI 0.98–1.01) for MTHFR gene 1298 A>C polymorphism and breast cancer susceptibility. In the subgroup
analysis stratified by source of control, decreased risk of breast cancer was found in studies with hospital-based
controls in dominant model (OR = 0.98, 95 % CI 0.96–1.00, P = 0.037).
Conclusions: Our meta-analysis suggested that there is no significant association between MTHFR gene 1298A>C
polymorphism and breast cancer susceptibility for overall population.
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Background
Breast cancer is the most frequently diagnosed cancer
among women, which contributed to 25 % of all can-
cer cases in women worldwide, and it is the leading
cause of female cancer-related death [1]. In UK,
48,034 women were diagnosed as breast cancer
holders in 2008, and in USA, more than 2.8 million
women suffered from breast cancer in 2015 [2, 3]. In
China, breast cancer mortality have also raised quickly
in recent years, from 3.53/100,000 in 1990–1992 to
4.25 in 2012 [4]. The high morbidity and mortality of
the disease lead to increasing global public health bur-
den gradually. It is widely accepted that several fac-
tors, such as hormonal, environmental, and genetic
factors as well as their interactions contribute to the
onset of breast cancer [5, 6]. In 1993, mutations in
breast cancer (BRCA1) gene were suggested to be
linked with high incidence of breast cancer in some
families [7]. Since then, many susceptible genes in-
volved in initiation and evolution of breast cancer
have been researched, and one of them, the methylene-
tetrahydrofolate reductase (MTHFR) gene has been
widely studied.
The MTHFR locus locates on chromosome 1 at the end
of short arm (1p36.6), which encodes enzymes relevant to
folates metabolism. The enzyme encoded by MTHFR gene
takes part in the irreversible conversion of 5,10-metylenete-
trahydrofolate to 5-methyltetrahydrofolate, which plays a
crucial role in homocysteine remethylation to methionine
[8]. Previous studies have indicated that functional single
nucleotide polymorphisms (SNPs) of MTHFR gene partici-
pate in the folate-metabolizing genetic pathway and are
fundamental during the synthesis, repair, and methylation
process of DNA, RNA, and protein, which may affect folate
and vitamin B12 level [9, 10]. Of these SNPs, 1298A>C
polymorphism is caused by A to C transition in exon 7 and
results in alanine in substitution of glutamine at codon 429
of the protein [11]. Subjects with mutated MTHFR
1298A>C genetic polymorphisms have higher plasma level
of homocysteine [12] and may be more susceptible to dif-
ferent kinds of cancers, including breast cancer.
Many studies have investigated the association between
MTHFR gene 1298A>C polymorphism and breast cancer
risk. However, the results are inconsistent, with some
studies found significant association [13, 14], while others
were not [15, 16]. Although previous meta-analysis has
tried to clarify the association [17], recently, several new
case-control studies have been published [18–20]. In order
to avoid the limitations of single case-control studies and
provide renewed evidence, we performed this updated
meta-analysis and tried to give a more precise and
comprehensive estimation of association between MTHFR




Two databases were electronically searched, including
PubMed and EMBASE, to retrieve studies analyzing the as-
sociation between breast cancer susceptibility and MTHFR
gene 1298A>C polymorphism until January 1, 2016.
Searching terms were “breast cancer” or “breast neoplasm”,
in combination with “methylenetetrahydrofolate reductase”
or “MTHFR” or “MTHFR A1298C” or “MTHFR 1298A>C”
or “rs1801131” or “Glu429Ala”, and in combination with,
“polymorphism” or “variant” or “genotype” or “allele”. We
also hand-checked the reference lists of all the included
studies to make sure no study was missed. Two researches
conducted the searches independently. If several publica-
tions carried out among same patients and controls, we
only included one study with the most complete data.
Inclusion criteria
We first performed initial screening of titles and abstract.
A second round screening was based on full-text reviews.
Studies were considered eligible if they met the following
criteria: (1) it was a case-control study in design; (2) it
evaluated the MTHFR gene 1298 A>C polymorphism and
breast cancer susceptibility; (3) breast cancer was patho-
logically confirmed for all of the patients; (4) sample sizes
and individual genotype frequencies in cases and controls
were available; and (5) cases and controls should be
matched.
Exclusion criteria
Researches were excluded if they met any one of the follow-
ing criteria: (1) data came from reviews or abstracts; (2)
genotype and allele frequencies were both unavailable; (3)
subjects with other malignant tumor were included in con-
trols; (4) repeatedly published literature; (5) not breast can-
cer susceptibility outcome; and (6) controls were chosen
from women with a family history of breast cancer or with
other kinds of malignant tumors.
Data extraction and quality assessment
Two reviewers independently searched and selected litera-
ture, and then, extracted relevant data according to a data
extraction form. Disagreements were solved by discussion
until consensus was made. The extracted data including
the first author, year of publication, country of origin, eth-
nicity of the study population, source of control, sample
size, the genotype and allele frequencies of the MTHFR
gene 1298A>C polymorphism, and information of Hardy-
Weinberg equilibrium (HWE) in control groups. Different
ethnicity descents were categorized as Caucasian, Asian,
African, and if studies were with more than one ethnicity,
they were categorized as mixed ethnicity.
For each included study, the quality assessment was
conducted according to the STrengthening the REporting
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of Genetic Association (STREGA) studies). If the study
met all or most of the criteria in this approach, it would
be classified as “++” or “high quality”. For study in which
some of the criteria were fulfilled and the others were not
likely to change the results and conclusions, it would be
graded as “+” or “moderate quality”. For studies fulfilled
few or no criteria and the results were thought to be with
non-ignorable bias, it would be classified as “−” or “low
quality” [21].
Statistical analysis
Data analysis was conducted using STATA 11.0 software
(Stata Statistical software, College Station, TX, USA,
www.stata.com). Odds ratio (OR) and its corresponding
95 % confidence intervals (95 % CI) were used to evalu-
ate the strength of association between MTHFR gene
1298A>C polymorphism and breast cancer susceptibility.
Heterogeneity among included studies was tested using
chi-square-based Q test and I2 test. Phet < 0.05 or I
2 >
50 % were considered as statistically significant for het-
erogeneity. The Mantel-Haenszel method was used for
fix-effect model if no heterogeneity was found. Other-
wise, the DerSimonian-Laird random-effect model was
used. Fix-effect model considers that across all studies,
the genetic factors have similar effects on genetic dis-
order susceptibility and the observed differences among
studies are caused just by chance [22]. Random-effect
model considers that different studies may have substan-
tial diversity, and it calculates within- as well as
between-study difference [23]. Five comparison genetic
models were used to assess the association between
MTHFR gene 1298A>C polymorphism and breast cancer
susceptibility. We assessed the dominant model (AA +
AC vs. CC), recessive model (AA vs. AC + CC), allele
contrast genetic model (A vs. C), the heterozygote com-
parison (AC vs. CC), and the homozygote comparison
(AA vs. CC). P < 0.05 showed the statistical significance.
HWE was tested for included studies if no relevant in-
formation was provided in original research. Sensitivity
analyses were conducted by omitting individual studies
sequentially. Moreover, we performed subgroup analysis
stratified by ethnicity, source of control, and deviation
from HWE. Publication bias was quantitatively assessed
by Egger’s linear regression test [24] and visual inspec-
tion of Begg’s funnel plots.
Results
Literature search
We initially identified 373 potentially relevant studies
from searching the two databases and the reference lists
of relevant studies. Firstly, we eliminated duplications,
and after this procedure, 248 studies were retained. After
reading the titles and abstracts, we excluded 193 studies.
Among them, 89 were not case-control studies, 91 were
irrelevant to MTHFR polymorphism or breast cancer
susceptibility, and 13 were reviews or meta-analysis.
Then, we read the full texts of the 55 retained articles
and 17 were excluded. Of them, 11 was irrelevant to
1298A>C polymorphism, four focused on breast cancer
mortality, one conducted among the same patients and
controls with another study, but provided less completed
data, and for one study, the controls were chosen from
BRCA1 carriers. We finally identified 38 case-control
studies eligible for the meta-analysis [13–16, 18–20, 25–
55], including 18,686 cases and 22,299 controls. A flow
chart of data selection was presented in Fig. 1.
Main characteristics of included studies
Table 1 presents the main characteristics and genotype fre-
quencies of the included studies. Of the 38 studies, 15 stud-
ies were carried out among Asians, 13 among Caucasians,
and 10 among mixed populations. All studies included were
case-control studies in design, and all patients with breast
cancer fulfilled the pathological diagnosis. The number
ranged from 35 to 1986 for cases, and 33 to 2414 for con-
trols. In 21 studies, controls were normal healthy people
randomly recruited from general population, and in 15
studies, controls were recruited from hospital among
women with benign disease or through women going to
hospital for routine physical examines, but in the two stud-
ies, we were unable to find out the source of controls. In
most of the included studies, controls were matched with
cases in ethnicity and age. In quality assessment, 17 studies
included were categorized as “high quality,” and 21 as
“moderate quality” (Table 1). In eight studies, the genotype
distributions in control groups were deviated from HWE
(Table 1).
Quantitative data analysis
Association between MTHFR gene 1298A>C polymorphism
and breast cancer susceptibility
The results of the five genetic models testing MTHFR gene
1298A>C polymorphism and breast cancer susceptibility
are presented in Table 2. In the dominant model (AA + AC
vs. CC), P value for heterogeneity was 0.000, and I2 was
50.5 %, indicating significant heterogeneity among studies.
Thus, random-effect model was used. The overall effect Z
value was 1.12 (P = 0.218) and OR was 0.99 (95 % CI 0.99–
1.00), suggesting that no association was found in the dom-
inant model. The Egger’s linear regression test indicated
that there was some evidence of publication bias in this
model (Egger, P = 0.01). Other four genetic models were
also performed (Table 2), but no association was found. In
subgroup analyses stratified by source of control, a signifi-
cant decrease in breast cancer susceptibility was found in
hospital-based controls in dominant model (OR = 0.98,
95 % CI 0.96–1.00, P = 0.037), but not in allele contrast
genetic model (OR = 0.97, 95 % CI 0.94–1.00, P = 0.092)
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(Table 3). Moreover, the results showed that in subgroups
of Asians and population-based studies, the heterogeneity
among studies was significantly reduced. Figure 2 shows
the forest plot of the dominant model testing the associ-
ation between MTHFR 1298A>C polymorphism and breast
cancer risk, stratified by ethnicity. Figure 3 shows the forest
plot of the dominant model testing the association between
MTHFR 1298A>C polymorphism and breast cancer risk,
stratified by source of control.
Sensitivity analysis and publication bias
Sensitivity analyses were conducted by omitting each data-
set sequentially, and the result did not change under any
genetic model. Sensitivity analysis suggested that for all of
the five genetic comparisons of MTHFR gene 1298A>C
polymorphism and breast cancer susceptibility, the results
were statistically robust.
Visual inspection of Begg’s funnel plots identified
the substantial asymmetry for dominant model, the al-
lele contrast genetic model, the heterozygote compari-
son, and the homozygote comparison. The Egger’s
linear regression test also indicated the similar results
(P < 0.05 for all models tested except the recessive
genetic model) (Table 2). Figure 4 shows the Begg’s
funnel plot under dominant model of MTHFR
1298A>C polymorphism.
Fig. 1 Flow chart of data selection
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Discussion
MTHFR is an essential gene in the one-carbon metabol-
ism pathway. During the past few years, many meta-
analyses assessing the association between MTHFR gene
polymorphism and cancer risks have been published, in-
cluding liver cancer, ovary cancer, lung cancer, gastric
Table 1 The main characteristics of studies included in this meta-analysis and the distribution of MTHFR gene 1298A>C genotypes
and alleles among cases and controls
First author Year Ethnicity Source
of
controls
Cases Controls Cases Controls Deviation
from HWE
Quality
gradeAA AC CC AA AC CC A C A C
Aram 2012 Caucasian HB 35 55 20 30 75 5 125 95 135 85 Yes +
Awwad 2015 Asian PB 68 61 17 58 64 13 197 95 180 90 No ++
Carvalho Barbosa Rde 2012 Mixed PB 68 80 17 72 84 9 216 114 228 102 Yes +
Chen 2005 Mixed PB 558 417 87 536 457 110 1533 591 1529 677 No ++
Cheng 2008 Asian HB 207 125 19 310 207 17 539 163 827 241 Yes +
Chou 2006 Asian HB 104 30 8 172 95 18 238 46 439 131 No +
Ergul 2003 Caucasian HB 50 48 20 90 85 18 148 88 265 121 No +
Ericson 2009 Caucasian PB 242 242 57 487 480 105 726 356 1454 690 No ++
Forsti 2004 Caucasian NA 94 102 27 133 127 38 290 156 393 203 No +
Gao 2009 Asian PB 446 165 9 425 188 11 1057 183 1038 210 No ++
He 2014 Asian HB 138 132 40 173 155 53 408 212 501 261 No +
Hosseini 2011 Caucasian HB 36 96 162 60 135 105 168 420 255 345 No +
Inoue 2008 Asian PB 225 139 16 387 234 41 589 171 1008 316 No ++
Justenhoven 2005 Caucasian PB 273 256 53 295 266 73 802 362 856 412 No ++
Kakkoura 2015 Mixed PB 138 465 468 150 500 484 741 1401 800 1468 No ++
Kotsopoulos 2008 Caucasian HB 466 390 85 398 309 73 1322 560 1105 455 No +
Lajin 2012 Caucasian HB 44 52 23 65 48 13 140 98 178 74 No +
Le Marchand 2004 Mixed PB 741 372 77 1493 801 120 1854 526 3787 1041 No ++
Lissowska 2007 Caucasian PB 892 874 220 1086 941 251 2658 1314 3113 1443 Yes +
Liu 2013 Asian HB 206 176 53 214 172 49 588 282 600 270 No +
Lopez-Cortes 2015 Mix PB 110 3 1 191 3 1 223 5 385 5 Yes +
Lu 2015 Asian HB 369 172 19 352 185 23 910 210 889 231 No +
Ma 2009 Mixed HB 269 168 21 279 157 22 706 210 715 201 No +
Mir 2008 Asian NA 15 19 1 11 22 0 49 21 44 22 Yes +
Ozen 2013 Mix PB 17 29 5 71 35 0 63 39 177 35 Yes +
Papandreou 2012 Caucasian HB 129 135 36 136 116 31 393 207 388 178 No +
Platek 2009 Mix PB 443 402 83 842 758 181 1288 568 2442 1120 No ++
Qi 2004 Asian PB 155 58 4 144 71 3 368 66 359 77 No ++
Sangrajrang 2010 Asian HB 302 223 38 258 206 23 827 299 722 252 Yes +
Sharp 2002 Caucasian PB 27 25 3 24 25 11 79 31 73 47 No ++
Shrubsole 2004 Asian PB 768 311 42 824 344 40 1847 395 1992 424 No ++
Stevens 2007 Mixed PB 224 228 42 252 201 40 676 312 705 281 No ++
Vainer 2010 Caucasian HB 398 353 80 379 330 76 1149 513 1088 482 No +
Weiwei 2014 Asian HB 135 129 32 151 130 25 399 193 432 180 No +
Wu 2012 Asian PB 37 32 6 42 28 5 106 44 112 38 No ++
Xu 2007 Mixed PB 558 417 87 536 457 110 1533 591 1529 677 No ++
Zhang 2015 Asian PB 98 87 31 105 84 27 283 149 294 138 No ++
Ziva Cerne 2011 Caucasian PB 258 219 47 131 117 21 735 313 379 159 No ++
PB population-based study, HB hospital-based study, NA not available, HWE Hardy-Weinberg equilibrium
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cancer, pancreatic cancer, cervical cancer, and esopha-
geal cancer [56–60]. Genetic variation in enzymes and
proteins involved in folate metabolism is also a rational
candidate for studying the genetic of breast cancer.
Therefore, the interest in MTHFR gene 1298A>C poly-
morphism and breast cancer susceptibility has existed
for a long time. In 2002, Sharp et al. for the first time
published a case-control study estimating the association
between MTHFR gene 1298A>C polymorphism and
breast cancer risk. Their result suggested that risk was
significantly lower for the 1298CC genotype compared
to AA genotype (OR = 0.24, 95 % CI 0.06–0.97) [49].
However, after that, a number of subsequent studies
were conducted and their results were inconsistent, with
some studies showed significant associations while
others were not. The inconsistency may be caused by
several reasons. First of all, although in vitro, the variant
genotype is associated with a substantial decrease in en-
zymatic activity [11], this functional polymorphism may
be an important but not the exclusive influencing factor
in etiology and pathogenesis of breast cancer. Special
lifestyle and environmental factors, such as tea drinking
[61], dietary intake of folate, vitamin B6 and B12 [62],
physical activities [63], long-term oral contraceptive use
[64], and hormone replacement therapy use [65], are
possibly confounding factors taking part in the disease
etiology. Moreover, differences in patient choosing
criteria, ethnicity, sample size, and sources of control
could contribute to inconsistency. Hence, it is necessary
to conduct a meta-analysis providing quantitative ap-
proach for pooling the results of all studies with the
same purpose and explaining the overall estimation as
well as the diversity.
Our study has important strengths. All original studies
used a case-control study design, which is a useful tool
to identify gene and disease associations. However, indi-
vidual genotype case-control studies could not be based
on a large number of subjects or contain patients in dif-
ferent ethnicities, and thus has insufficient statistical
power. Our meta-analysis based on case-control studies
involving 40,985 subjects brings to light that there is no
significant association between MTHFR gene 1298A>C
polymorphism and breast cancer susceptibility for over-
all population, with ORs from 0.99 to 1.00 and narrow
95 % CIs for all of the five genetic models. Moreover, in
our study, no association was found in different ethnici-
ties or in population-based studies, which thereby
strengthened this association. As shown in our meta-
analysis, studies with hospital-based design or controls
deviated from HWE had a weak, but statistical signifi-
cant decreased association with breast cancer in domin-
ant model. However, in these two kinds of studies, the
controls may not represent the whole population and
thereby, the results from them should be interpreted
Table 2 Summary of different genetic model comparison results of MTHFR gene 1298A>C polymorphism
Genetic model OR (95 % CI) Z P value I2 % Phet Effect
model
Egger’s test
t value P value
AA + AC vs. CC 0.99 (0.99–1.00) 1.23 0.218 50.5 0.000 R −2.72 0.010
AA vs. AC + CC 1.00 (0.97–1.02) 0.15 0.880 35.9 0.016 R −1.45 0.155
AA vs. CC 0.99 (0.98–1.01) 0.86 0.390 43.8 0.002 R −2.75 0.014
AC vs. CC 0.99 (0.97–1.00) 1.48 0.138 41.2 0.005 R −2.55 0.015
A vs. C 0.99 (0.98–1.01) 0.92 0.360 55.5 0.000 R −2.27 0.029
OR odds ratio, CI confidence interval, R random-effect model, Phet P value for heterogeneity
P < 0.05 stands for statistical significance
Table 3 Results of subgroup analyses of MTHFR gene 1298A>C polymorphism
Stratified by Comparison Number
of
datasets
Dominant genetic model Allele contrast
OR (95 % CI) P value OR (95 % CI) P value
Ethnicity Asian 15 1.00 (0.99–1.00) 0.506 1.01 (0.99–1.02) 0.249
Caucasian 13 0.98 (0.95–1.01) 0.129 0.97 (0.93–1.00) 0.059
Mixed 10 0.99 (0.99–1.00) 0.852 0.99 (0.98–1.01) 0.660
Source of control PB 21 1.00 (0.99–1.01) 0.931 1.00 (0.99–1.02) 0.830
HB 15 0.98 (0.96–1.00) 0.037 0.97 (0.94–1.00) 0.092
NA 2 0.99 (0.94–1.04) 0.793 0.99 (0.91–1.08) 0.892
Deviation from HWE Yes 8 0.98 (0.95–1.00) 0.019 0.98 (0.95–1.01) 0.102
No 30 1.00 (0.99–1.01) 0.909 1.00 (0.98–1.01) 0.801
PB population-based study, HB hospital-based study, NA not available
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with caution. Overall, our meta-analysis based on 38
case-control studies provided reliable and comprehen-
sive estimations. The association in the five genetic
models sustained unchanged in the sensitivity analysis,
which further confirmed the results of main analysis.
It is also important to mention the heterogeneity existed
in this study. For all genetic models in the main analysis, P
value for heterogeneity was less than 0.05, indicating signifi-
cant heterogeneity among the included studies. Finding the
potential sources of heterogeneity is an important part of
meta-analysis, which can greatly influence the results of the
research. To detect the possible source of heterogeneity in
our meta-analysis, we performed the subgroup analysis
stratified by ethnicity, source of control, and deviation from
HWE. When stratified by ethnicity and source of control,
the heterogeneity was significantly decreased in Asian and
population-based subgroups. Therefore, the different ethni-
city and source of control may contribute to the overall
heterogeneity. However, heterogeneity still existed in
Caucasian, mixed ethnicity, and hospital-based control sub-
groups, suggesting that ethnicity and source of control did
not fully explain the heterogeneity among studies. Further
studies may try to explore in interactions between different
factors and to minimize the heterogeneity in subgroups.
Several previous meta-analyses have been published to
analyze the association between MTHFR gene polymor-
phisms and breast cancer susceptibility, and the majority of
them concerned on 677C>T polymorphism [66–69]. Two
studies published in 2014 have detected the 1298A>C poly-
morphism [17, 70]. The main result of our study was con-
sistent with the previous meta-analyses. Comparing with
these two studies, our study has some important improve-
ments. In 2014–2015, some new studies were published
and they were included in our meta-analysis. Through strict
methodological process, we provided a more comprehen-
sive view of included studies. The abovementioned meta-
analyses only stratified by ethnicity to test if there existed
differences in variant ethnicities. In present study, we also
Fig. 2 Shows the forest plot of the dominant model testing the association between MTHFR 1298A>C polymorphism and breast cancer risk,
stratified by ethnicity
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Fig. 3 Shows the forest plot of the dominant model testing the association between MTHFR 1298A>C polymorphism and breast cancer risk,
stratified by source of control
Fig. 4 Begg’s funnel plot under dominant model of MTHFR 1298A>C polymorphism
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conducted subgroup study stratified by source of control
and deviation from HWE in control group, to analyze if
there were differences between subgroups.
We should also pay attention to the several limitations
in our study, which may affect the result. Firstly, we only
included published studies meeting our inclusion criteria
from two databases, similar studies in other databases
and unpublished researches may have been missed, and
this is also the main reason for the publication bias we
found in four of the five genetic models. Secondly, the
control groups in some of the included studies were de-
viated from HWE, which may fail to represent the whole
population and have some effects on the overall estima-
tion. Thirdly, although the results from subgroup and
sensitivity analyses were quite similar to the main ana-
lysis, significant heterogeneity was detected in all five
genetic models of MTHFR gene 1298A>C polymorphism
and breast cancer susceptibility. Different characteristics
in study population and study design may contribute to
the heterogeneity. Considering that meta-analysis is a
kind of retrospective research and may easily be affected
by methodological deficiencies of the included studies,
we developed a detailed protocol before conducting this
analysis, to ensure the quality of our research.
Conclusions
From the combination results of currently included stud-
ies, our meta-analysis suggested that there is no significant
association between MTHFR gene 1298A>C polymorph-
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